Wednesday broker round-up
22nd Jan 2020 12:52
(Sharecast News) - Experian: Morgan Stanley upgrades to overweight with a target price of 2,950p.
Read moreAstraZeneca clears regulatory hurdles with 'Imfinzi' and 'Lynparza'
20th Jan 2020 07:19
(Sharecast News) - AstraZeneca announced on Monday that its 'Imfinzi' (durvalumab) and tremelimumab, an anti-CTLA4 antibody and potential new medicine, have both been granted orphan drug designation by the Food and Drug Administration (FDA) in the United States, for the treatment of hepatocellular carcinoma (HCC), which is the most common type of liver cancer.
Read moreThursday broker round-up
16th Jan 2020 12:58
(Sharecast News) - Diageo: Jefferies downgrades to hold with a target price of 3,600p
Read moreAstraZeneca upbeat on 'Lynparza' decision, closes 'Epanova' trial
13th Jan 2020 07:32
(Sharecast News) - AstraZeneca and its partner MSD announced that a supplemental New Drug Application for 'Lynparza' - olaparib - in combination with bevacizumab, has been accepted and granted priority review status in the United States for the maintenance treatment of patients with advanced ovarian cancer who are in complete or partial response to first-line platinum-based chemotherapy with bevacizumab.
Read moreAstraZeneca clears regulatory hurdles in US and China
6th Jan 2020 08:22
(Sharecast News) - AstraZeneca cleared two regulatory approvals on Monday - one for 'Farxiga' in the United States, and one for 'Lokelma' in China.
Read moreAstraZeneca gets US approval for 'Lynparza' in pancreatic cancer
30th Dec 2019 08:15
(Sharecast News) - AstraZeneca announced on Monday, alongside its partner MSD, that 'Lynparza', or olaparib, has been approved in the United States for the maintenance treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm) metastatic pancreatic adenocarcinoma, or pancreatic cancer, whose disease had not progressed on at least 16 weeks of a first-line platinum-based chemotherapy regimen.
Read moreAstraZeneca upbeat on approvals in China and the US
23rd Dec 2019 07:40
(Sharecast News) - AstraZeneca announced on Monday that budesonide/glycopyrronium/formoterol fumarate has been approved in China for the maintenance treatment of chronic obstructive pulmonary disease (COPD).
Read moreFriday broker round-up
20th Dec 2019 12:28
(Sharecast News) - Segro: HSBC downgrades to hold with a target price of 869p.
Read moreAstraZeneca sells cancer drug duo rights to Juvisé
20th Dec 2019 07:30
(Sharecast News) - AstraZeneca on Friday said it had agreed to sell the commercial rights to Arimidex (anastrozole) and Casodex (bicalutamide) to Juvisé Pharmaceuticals in several European, African and other countries.
Read moreAstraZeneca offloads 'Seroquel' rights in Europe and Russia
16th Dec 2019 07:42
(Sharecast News) - AstraZeneca has completed an agreement to divest its commercial rights to Seroquel - quetiapine fumarate immediate release - and Seroquel XR - quetiapine fumarate extended release - in Europe and Russia, it announced on Monday, to Cheplapharm Arzneimittel.
Read moreThursday broker round-up
12th Dec 2019 13:38
(Sharecast News) - Synthomer: JP Morgan upgrades to neutral with a target price of 300p.
Read moreAstraZeneca gets Imfinzi approval in China
12th Dec 2019 07:32
(Sharecast News) - AstraZeneca announced on Thursday that it has received marketing authorisation from China's National Medical Products Administration (NMPA) for 'Imfinzi' - durvalumab - for the treatment of patients with unresectable, stage 3 non-small cell lung cancer (NSCLC), whose disease has not progressed following concurrent platinum-based chemotherapy and radiation therapy (CRT).
Read moreTuesday broker round-up
10th Dec 2019 08:29
(Sharecast News) - ASOS: HSBC upgrades to buy with a target price of 3,615p.
Read moreDeepMatter shares surge as it announces AstraZeneca collaboration
9th Dec 2019 14:07
(Sharecast News) - DeepMatter shares surged on Monday, after it announced a collaboration with AstraZeneca to use digital technologies to improve the productivity and reproducibility of compound synthesis.
Read moreAstraZeneca's Lynparza approved for use in China
5th Dec 2019 08:27
(Sharecast News) - Biopharmaceutical company AstraZeneca announced on Thursday that Lynparza had been approved in China as a first-line maintenance therapy in BRCA-mutated advanced ovarian cancer.
Read more